Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Outlook 2020-2030

Europe Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market Analysis 2020-2030

The Europe pharmaceutical contract development and manufacturing organization (CDMO) market is anticipated to grow with a CAGR of 6.7% during the forecast period, i.e., 2021-2030. Factors such as the growing prevalence of chronic diseases in the region, and the need for advanced drugs amongst the pharmaceutical drug manufacturers to treat these diseases, are anticipated to drive the growth of the market in the coming years. Moreover, rising research and developments in the field of medical sciences, and the growing need for high potency active pharmaceutical ingredients (HPAPI) amongst the pharmaceutical companies are some of the additional factors projected to drive the growth of the market in the coming years. The market is estimated to garner a revenue of close to USD 39900 Million by the end of 2030, up from a revenue of near to USD 21130 Million in the year 2020.

The Europe pharmaceutical contract development and manufacturing organization (CDMO) market is segmented into numerous segments, which include segmentation by category, therapeutic application, end-user, service type, and by country. Based on end-user, the market is segmented into pharmaceutical & biopharmaceutical companies, medical device companies, and academic institutes. The pharmaceutical & biopharmaceutical companies segment, out of all the other segments, is anticipated to garner the largest revenue of around USD 27750 Million by the end of 2030, up from a revenue of near to USD 14770 Million in the year 2020.

On the basis of geographical analysis, the Europe pharmaceutical contract development and manufacturing organization (CDMO) market is segmented into Germany, United Kingdom, France, Italy, Spain, Russia, and the Rest of Europe. The market in Italy, amongst the market in all the other countries, is anticipated to garner the largest revenue of near to USD 8940 Million by the end of 2030. Moreover, in the year 2020, the market in the nation generated a revenue of about USD 4860 Million.

Some of the prominent industry leaders in the Europe pharmaceutical contract development and manufacturing organization (CDMO) market that are included in our report are Hangzhou Tigermed Consulting Co., Ltd, ICON plc, IQVIA Inc., LSK Global Pharma Services Co., Ltd., Parexel International Corporation, PPD Inc., Almac Group, Quanticate International Limited, Samsung Biologics, Syneos Health, Wuxi Apptec Co., Ltd., Delpharm Holding, Evonik Industries AG, Siegfried Holding AG, Aenova Group, Baxter International, Inc., Boehringer Ingelheim International GmbH, Catalent, Inc., Famar Group, Jubilant Pharmova Limited, Lonza, CMIC HOLDINGS Co., LTD., Labcorp Drug Development, Thermo Fisher Scientific Inc., Pfizer Inc., Recipharm AB, Vetter Pharma-Fertigung GmbH & Co. KG, Charles River Laboratories International, Inc., and others.